Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Neurocrine Biosciences

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities8.80%
Size of stake in company1.80%
Market capitalizationUSD 13.9 bn

Sector

Neurology

Main candidate

Ingrezza

Main indications

Tardive Dyskinesia, Chorea-Huntington’s Disease 

About the company

Neurocrine Biosciences is a biotechnology company specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. The company lead product Ingrezza (VMAT2 inhibitor) is approved in the US for the treatment of tardive dyskinesia (a condition where patients have involuntary movements that cannot be controlled) and as of August 2023 also for the treatment of Chorea-Huntington’s Disease. On the pipeline side, the company is preparing to file an NDA for crinecerfont, a CRF-R1 antagonist, for the treatment of Congenital Adrenal Hyperplasia (CAH).

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.